Inhibition of the VEGF expression and cell growth in hepatocellular carcinoma by blocking HIF-1α and Smad3 binding site in VEGF promoter

Abstract

In order to investigate the inhibitory effects on the vascular endothelial growth factor (VEGF) expression and cell growth in hapatocellular carcinoma (HCC) by blocking HIF-1α and Smad3 binding site in the VEGF promoter, antisense oligodeoxynucleotides (ASODN) were designed to block HIF-1α and Smad3 binding site in the VEGF promoter. Different concentrations of ASODN and ODN were transfected into HCC cells respectively. The expression of VEGF mRNA and protein was detected by SABC, Western blot and RT-PCR techniques and the inhibitory effects on the expression of VEGF and cell growth of the HCC cells stimulated by the supernatants were determined by using MTT method. Immunohistochestry revealed that after co-inoculation of hepatocellular carcinoma cells with different concentrations of ODN and ASODN for 48 h, there was no significant difference in the expression of VEGF protein between ODN group and control group (P>0.05), but there was significant difference between ASODN, the difference was very significant (P<0.01). Western blot and RT-PCR revealed that, after treatment for 48 h at a concentration of 10 μmol/L, the integral gray levels and RNA odds were 59743.2±10412.5 and 0.783±0.032 in ODN group, and 38694.5±10925.1 and 0.468±0.015 in ASODN group, respectively, with the difference being very significant (P<0.01). Antisense ODN could inhibit the growth of HCC cells in a concentration-dependent manner. It was concluded that anti-gene technique of aiming at HIF-1α action site in the VEGF promoter could suppress the VEGF expression and inhibit HCC cell growth, and it is promising that anti-gene technique works as a new gene therapeutic tool for anti-angiogenesis of HCC.

Keywords

sense/antisense oligodeoxynucleotide / hepatocellular carcinoma / vascular endothelial growth factor / hypoxia-inducible factor-1α

References

[1] VaupelP. The role of hypoxia-induced factors in tumor progression. Oncologist, 2004, 5: 10-17

[2] StoeltzingO, McCartyM F, WeyJ S, et al.. Role of HIF-1α in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst, 2004, 96: 946-956

[3] ChoiK S, BaeM K, JeongJ W, et al.. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol, 2003, 36: 120-127

[4] BrackenC P, WhitelawM L, PeetD J. The hypoxia-inducible factors, key transcriptional regulators of hypoxic responses. Cell Mol Life Sci, 2003, 60: 1376-1393

[5] RapisardrA, UranchimegG, ScudieroD A, et al.. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res, 2002, 62: 4316-4324

[6] MaxwellP H, DachsG U, GleadleJ M, et al.. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci, 1997, 94: 8104-8109

[7] TandleA, LibuttiS K. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clin Adv Hematol Oncol, 2003, 1: 41-48

[8] ManleyP W, Martiny-BaronG, SchlaeppiJ M, et al.. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs, 2002, 11: 1715-1736

[9] ZhaoY, QiuG X. Relationship between vascular endothelial growth factor expression and angiogenesis in osteosarcoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (Chinese), 2001, 23: 619-621

[10] Sanchez-ElsnerT, BotellaL M, VelascoB, et al.. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. JBC, 2001, 276: 38 527-38 535

[11] BianX Y. MTT assay and its application. Foreign Med Sci: Section Clin Biochem Lab Sci (Chines), 1998, 19: 83-85

[12] SemenzaG L, RothP H, FangH M, et al.. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem, 1994, 269: 23757-23763

[13] LiuY, CoxS R, MoritaT, et al.. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res, 1995, 77: 638-643

[14] JiangB H, RueE, WangG L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem, 1996, 271: 17771-17778

[15] DingL, ChenX P, WangH P. Inhibition of hepatocellular carcinoma cell growth by blocking HIF-1α binding site in the VEGF promoter. Acta Med Univ Technol Huazhong (Chinese), 2005, 34: 750-753